Chinese Journal of Integrative Medicine

, Volume 17, Issue 12, pp 933–936 | Cite as

Clinical evaluation of oral Fructus Bruceae oil combined with radiotherapy for the treatment of esophageal cancer

  • Guo-yong Shan (单国用)
  • Song Zhang (张 松)
  • Guo-wen Li (李国文)
  • Yong-shun Chen (陈永顺)
  • Xing-an Liu (刘兴安)
  • Jian-kun Wang (王建坤)
Clinical Experience



To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer.


A total of 80 patients with esophageal cancer were equally and randomly divided into two groups. The patients in Group A were treated with radiotherapy (60–65 Gy, 6–7 weeks) and oral Fructus bruceae oil (20 mL, 3 times per day for 12 weeks), while the patients in Group B were treated with radiotherapy alone. The short-term effect was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) and quality of life (QOL) was evaluated by the Karnofsky scoring (KFS). The outcome measures included complete remission (CR) rate, partial remission (PR) rate, effective rate as CR+PR, patients’ QOL and adverse effects.


After 12-week treatment, the CR and CR+PR were significantly higher in Group A than those in Group B (P <0.05). There was an improvement in esophageal obstruction of 87.5% and 60.0%, respectively, and in KFS of 84.6% and 43.9%, respectively, in Groups A and B.


Oral medication with oral Fructus bruceae oil could effectively improve the efficacy of radiotherapy in esophageal cancer, including a reduction in esophageal obstruction, and also reduce the side effects of radiotherapy; thus it would be very promising for clinical application.


Fructus bruceae esophageal cancer radiotherapy Chinese medicine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007;57:43–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Sun Y, Zhou JC, eds. Clinical cancer physician manual. 4th ed. Beijing: People’s Medical Publishing House; 2003:529.Google Scholar
  3. 3.
    Farzad M, De luca MC, Rubino G, Pirtoli L, Pepi F, Sebaste L, et al. Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice. Radiol med 2001;102:72–74PubMedGoogle Scholar
  4. 4.
    Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 2009;39:638–643PubMedCrossRefGoogle Scholar
  5. 5.
    Noël G, Mazeron JJ, Favaudon V. Chemoradiotherapy of solid tumours in the adult: current views and perspectives. Bull Cancer 2003;90:85–92.PubMedGoogle Scholar
  6. 6.
    Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. Clin Oncol 2000;18:455–462.Google Scholar
  7. 7.
    Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PETCT Comparison to histopathologic and clinical response evaluation. Radiother Oncol 2008;89:278–286.PubMedCrossRefGoogle Scholar
  8. 8.
    Chu DT. Contemporary tumor medical treatment scheme evaluation. 2nd ed. Beijing: Beijing Medical University Press; 2005:123–124.Google Scholar
  9. 9.
    Bedford JL, Viviers L, Guzel z, Childs PJ, Webb S, Tait DM. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 2000;57:183–193.PubMedCrossRefGoogle Scholar
  10. 10.
    Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 2004;21:109–122.Google Scholar
  11. 11.
    Zhou LH, Wu J, Jiang XD. Clinical observation of radiotherapy with Docetaxel for middle-late esophageal cancer. J Pract Oncol 2010;24:68–71.Google Scholar
  12. 12.
    Lu JM, Wang LH, Zhou ZM, Zhou ZM, Zhang HX, Chen DF. Phase II study on concomitant paclitaxel and radiotherapy for locally advanced non-small cell lung cancer. Chin J Radiat Oncol (Chin) 2004;13:89–91.Google Scholar
  13. 13.
    Zhao BF. Radiosensitizing effects of clinical research with taxol for esophageal radiotherapy. Chin J Celiopathy (Chin) 2004;4:880–883.Google Scholar
  14. 14.
    Ding CX, Suo YD. Research progress of chemical constituents and pharmacological on Fructus bruceae. Chin Tradit Patent Med (Chin) 2006;28:117–119.Google Scholar
  15. 15.
    Yue B, Dong GY, Yu XH. Clinical efficacy of Fructus bruceae with body-gamma knife in treating oesophageal cancer. Med Innovat China (Chin) 2009;6(20):52–53.Google Scholar
  16. 16.
    Yuan GR. The efficacy of Fructus bruceae on topical therapy for superficial malignant tumor of 2 cases reported. Chin J Surg Integr Tradit West Med (Chin) 2004;10:252.Google Scholar
  17. 17.
    Su QS, Lin Y, Yang JH, You ZH, Liu C, Shi ZM. Curative effects of treatment on clinical observation with Fructus bruceae for advanced breast malignant tumor. J Postgrad Med 2006;19:765–766.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Guo-yong Shan (单国用)
    • 1
  • Song Zhang (张 松)
    • 1
  • Guo-wen Li (李国文)
    • 2
  • Yong-shun Chen (陈永顺)
    • 1
  • Xing-an Liu (刘兴安)
    • 1
  • Jian-kun Wang (王建坤)
    • 1
  1. 1.Department of Radiation OncologyZhengzhou People’s HospitalZhengzhouChina
  2. 2.Department of Radiation OncologyAffiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations